{"id":257,"date":"2026-11-03T02:43:25","date_gmt":"2026-11-03T02:43:25","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=257"},"modified":"2026-11-03T02:43:25","modified_gmt":"2026-11-03T02:43:25","slug":"slow-substrate-inhibitors-of-sirt2-alkyl-branched-acyl-lysine-peptides-that-stall-the-enzyme-target-modality-intelligence-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/slow-substrate-inhibitors-of-sirt2-alkyl-branched-acyl-lysine-peptides-that-stall-the-enzyme-target-modality-intelligence-dossier\/","title":{"rendered":"Slow-Substrate Inhibitors of SIRT2: Alkyl-Branched Acyl-Lysine Peptides That Stall the Enzyme \u2014 Target &#038; Modality Intelligence Dossier"},"content":{"rendered":"<h2 class=\"wp-block-heading\">The problem: inhibiting a deacylase without a classic warhead<\/h2>\n\n<p>SIRT2 is an NAD<sup>+<\/sup>-dependent lysine deacylase implicated in cancer and neurodegeneration &mdash; it strips acetyl and long-chain acyl marks from substrates such as &alpha;-tubulin, NF-&kappa;B and FOXO. Drugging it selectively is hard: the human sirtuins (SIRT1&ndash;7) share a conserved catalytic core, and the most potent peptide inhibitors to date are <strong>mechanism-based<\/strong> &mdash; thioacyl-lysines (e.g. thiomyristoyl) that get partway through catalysis and form a <em>stalled covalent intermediate<\/em> with NAD<sup>+<\/sup>. That works, but a covalent NAD<sup>+<\/sup>-adduct is a liability for a chemical probe or a degrader payload.<\/p>\n\n<p>Friedrich, Jung, Schutkowski and co-workers (Halle \/ Freiburg) ask a sharper question: <strong>can you make an acyl-lysine that binds like a substrate, aligns perfectly for catalysis, and then simply refuses to turn over<\/strong> &mdash; without forming any covalent intermediate?<\/p>\n\n<h2 class=\"wp-block-heading\">The strategy: branch the acyl chain and stall the chemistry<\/h2>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"579\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_concept-1024x579.png\" alt=\"\" class=\"wp-image-254\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_concept-1024x579.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_concept-300x170.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_concept-768x434.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_concept-1536x868.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_concept-2048x1158.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">Slow-substrate inhibition: the acyl-lysine amide oxygen docks in the catalytically competent geometry on NAD<sup>+<\/sup>, but C&alpha;\/C&beta; branching blocks collapse of the intermediate &mdash; turning a substrate into a long-residence inhibitor with no covalent adduct. Concept schematic by Astinova Bio Labs.<\/figcaption><\/figure>\n\n<p>SIRT2 deacylation begins when the acyl-lysine&rsquo;s amide oxygen attacks the C1&prime; of the NAD<sup>+<\/sup> ribose (nicotinamide is cleaved; His187 orchestrates the transition state). The authors reasoned that <strong>steric bumps right at the reacting carbons<\/strong> would let the amide dock in the catalytically competent geometry but block the collapse of the intermediate &mdash; converting a substrate into a <strong>&ldquo;slow substrate&rdquo;<\/strong> with a long residence time and minimal turnover. No thiocarbonyl, no stalled covalent adduct: a cleaner mechanism of inhibition.<\/p>\n\n<h2 class=\"wp-block-heading\">The chemistry: methyl branches and cyclopropanes on a thia-acyl chain<\/h2>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"850\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_warheads-1024x850.png\" alt=\"\" class=\"wp-image-253\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_warheads-1024x850.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_warheads-300x249.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_warheads-768x638.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_warheads-1536x1276.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_warheads.png 1977w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">The N&epsilon;-acyl-lysine warhead: a 4-thiapalmitoyl chain branched at the reacting carbons. Unbranched (1) is a fast substrate; C&alpha; and C&beta; gem-dimethyl (4, 5) abolish turnover; a C&beta; cyclopropyl (7) is sub-nanomolar. Structures drawn by Astinova Bio Labs (RDKit); lysine shown as an Ac-Lys-NH<sub>2<\/sub> cap.<\/figcaption><\/figure>\n\n<p>The warhead is an N&epsilon;-acyl-lysine built on a TNF&alpha;-derived nonapeptide (with a 3-nitrotyrosine chromophore for HPLC readout of turnover). For synthetic access, a methylene in the acyl chain is swapped for a <strong>thioether<\/strong> &mdash; acrylic-acid HFIP esters undergo 1,4-addition of 1-dodecanethiol to give <strong>4-thiapalmitoyl<\/strong> chains, which are coupled to resin-bound peptide. Branching is then installed at the reacting carbons:<\/p>\n\n<ul class=\"wp-block-list\"><li><strong>Unbranched (1):<\/strong> a true substrate &mdash; quantitatively deacylated within 24 h.<\/li><li><strong>C&alpha; gem-dimethyl (4)<\/strong> and <strong>C&beta; gem-dimethyl (5):<\/strong> dimethyl substitution abolishes catalysis (3% and 6% conversion over 24 h). <strong>Peptide 5<\/strong> &mdash; and its truncated di-lysine version <strong>KK3 (5a)<\/strong> &mdash; is the lead: apparent <strong>Ki &asymp; 0.9 nM<\/strong>, in-vitro <strong>IC<sub>50<\/sub> 5 nM<\/strong>, cellular <strong>NanoBRET EC<sub>50<\/sub> 13 nM<\/strong>.<\/li><li><strong>C&beta; cyclopropyl (7):<\/strong> a rigid, planar bioisostere of the gem-dimethyl &mdash; <strong>sub-nanomolar IC<sub>50<\/sub><\/strong>, among the most potent SIRT2 inhibitors in the assay.<\/li><\/ul>\n\n<p>Extending the idea, the authors show that <strong>naturally\/drug-derived branched acyls<\/strong> &mdash; <strong>phytanoyl-<\/strong> and <strong>ibuprofenyl-lysine<\/strong> &mdash; also inhibit SIRT2, suggesting branched acylations may be endogenous slow-substrate signals.<\/p>\n\n<h2 class=\"wp-block-heading\">The structural proof: aligned on NAD+, caught mid-reaction<\/h2>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"890\" height=\"836\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_binding_8qtu.png\" alt=\"\" class=\"wp-image-255\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_binding_8qtu.png 890w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_binding_8qtu-300x282.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/sirt2_binding_8qtu-768x721.png 768w\" sizes=\"auto, (max-width: 890px) 100vw, 890px\" \/><figcaption class=\"wp-element-caption\">SIRT2&ndash;peptide 5&ndash;NAD<sup>+<\/sup> ternary complex (PDB 8QTU, 1.80 &Aring;): the branched acyl-lysine threads the hydrophobic channel (Phe96\/Phe119) with NAD<sup>+<\/sup> bound and catalytic His187 poised. The amide oxygen is aligned on the NAD<sup>+<\/sup> ribose C1&prime; &mdash; yet turnover stalls. Rendered by Astinova Bio Labs (3Dmol.js).<\/figcaption><\/figure>\n\n<p>Ternary <strong>SIRT2&ndash;peptide&ndash;NAD<sup>+<\/sup><\/strong> co-crystals nail the mechanism. In the SIRT2&ndash;5&ndash;NAD<sup>+<\/sup> complex (<strong>PDB 8QTU, 1.80 &Aring;<\/strong>), the branched acyl-lysine threads the hydrophobic channel (lined by Phe96, Phe119, Phe143\/190\/234 and the selectivity pocket) with NAD<sup>+<\/sup> bound simultaneously and the amide nitrogen making the canonical hydrogen bond to the Val233 backbone. In the companion SIRT2&ndash;4&ndash;NAD<sup>+<\/sup> structure (8QT4, 1.55 &Aring;), the amide oxygen sits <strong>3.3 &Aring; from the NAD<sup>+<\/sup> ribose C1&prime;<\/strong> &mdash; essentially identical to the 3.1 &Aring; of a native myristoyl substrate (4Y6O). So minimal turnover is <strong>not<\/strong> caused by misalignment or amide-bond torsion; the branch stalls the chemistry <em>after<\/em> the enzyme has done everything right. Comparing SIRT2 with SIRT1\/SIRT3 reveals isoform-specific acyl-chain trajectories that underlie selectivity (dimethyl branching favours SIRT2 over SIRT1).<\/p>\n\n<h2 class=\"wp-block-heading\">Why it matters<\/h2>\n\n<ul class=\"wp-block-list\"><li><strong>A cleaner inhibition logic for sirtuins.<\/strong> &ldquo;Slow substrate&rdquo; trades the covalent stalled intermediate of thioacyl inhibitors for a non-covalent, long-residence block &mdash; attractive for <strong>chemical probes and SIRT2-targeting degraders<\/strong> where a reactive NAD<sup>+<\/sup> adduct is unwanted.<\/li><li><strong>Potency comes from the channel, not the backbone.<\/strong> Truncated di-lysine analogues (KK) keep single-digit-nanomolar potency, pinpointing the hydrophobic acyl channel as the affinity driver &mdash; a clear handle for future small-molecule mimetics.<\/li><li><strong>Cellular validation.<\/strong> Optimized inhibitors show low-nanomolar target engagement (NanoBRET) and induce robust <strong>&alpha;-tubulin hyperacetylation<\/strong>, confirming on-target SIRT2 inhibition in cells.<\/li><li><strong>A design primitive worth stealing.<\/strong> Steric branching at the reacting atom &mdash; gem-dimethyl or a cyclopropane bioisostere &mdash; is a general way to freeze an enzyme in a competent-but-unproductive state. Expect it to travel beyond sirtuins.<\/li><\/ul>\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n<p><strong>Reference:<\/strong> Friedrich, F.; Meleshin, M.; Kalbas, D.; Kollmer, F.; Papenkordt, N.; Mauerer, A.; Ruprecht, J.; Hilscher, S.; Zessin, M.; Schiene-Fischer, C.; Zhang, L.; Graf, L.; Sippl, W.; Einsle, O.; Jung, M.; Schutkowski, M. &ldquo;Alkyl-Branched Acyl-Lysine Peptides as Potent Cell-Permeable Slow-Substrate Inhibitors of SIRT2.&rdquo; <em>J. Med. Chem.<\/em> <strong>2026<\/strong>. DOI: 10.1021\/acs.jmedchem.6c01275.<\/p>\n\n<p><em>All visuals are original to Astinova Bio Labs: warhead structures and the mechanism schematic drawn with RDKit\/Matplotlib; the binding view rendered with 3Dmol.js from the deposited co-crystal PDB 8QTU. No paper figures were reused.<\/em><\/p>\n\n<p><em>Astinova Bio Labs designs and makes molecules like these &mdash; warhead and mechanism-of-inhibition design, peptide and small-molecule synthesis, and structure-based analysis. <a href=\"https:\/\/astinovabiolabs.com\/\">Talk to us<\/a> about your target.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>A clever twist on sirtuin inhibition: acyl-lysine peptides branched at the reacting carbon dock perfectly on NAD+ but refuse to turn over. The lead (KK3) hits SIRT2 at 5 nM in vitro \/ 13 nM in cells, with no covalent intermediate \u2014 validated by 1.8 \u00c5 ternary co-crystals.<\/p>\n","protected":false},"author":1,"featured_media":252,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[58,49,84,85,37,82,64,80,81,83],"class_list":["post-257","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-chemistry","tag-chemical-probe","tag-epigenetics","tag-nad-deacylase","tag-neurodegeneration","tag-oncology","tag-peptide-inhibitors","tag-selectivity","tag-sirt2","tag-sirtuins","tag-slow-substrate-inhibition"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=257"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/257\/revisions"}],"predecessor-version":[{"id":258,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/257\/revisions\/258"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/252"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}